This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. Such statements are based on SI-BONE's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, especially the information contained in the section captioned "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.
2
Transforming & Leading the Sacropelvic Space
Large
Market
Competitive
Clinical and
Market
Leadership
Advantage
Educational Focus
$2.5 billion annual
Pioneering sacropelvic
5-year clinical data
SI-BONE SImulator™
U.S. opportunity
surgical solutions
advanced training
technology
279K potential U.S.
~65,000 procedures
>35 Exclusive iFuse
~160 academic
procedures per year
worldwide using
payor policies;
programs with training
iFuse Technology®
~160M U.S. exclusive
events
covered lives2
Less than 10%
Majority estimated U.S.
150 dedicated
~850 trained fellows
market penetration
market share iFuse1
field reps3
and residents
Sacropelvic product
portfolio & pipeline
Spinemarket, Inc. (2020)
As of October 1, 2021
As of December 31, 2021
3
Setup to Deliver Strong and Sustainable Long-term Growth
▪ 2009: iFuse
▪ Apr : SIFI
▪ Mar: iFuse 3D
IPO
Launched
Clinical Trial
(510K approval)
Aug : INSITE Clinical Trial
2009
2015
2017
2018
Product / solutions launched
Clinical trial results
Payor wins / surgeon reimbursement changes
▪ Apr: Expanded to
▪ May: SI SImulator
Adult Deformity -
launched
Bedrock
Sept: LOIS clinical Trial (5-yrdata)
20192020
Dec: CIGNA ▪ Jan: Surgeon payment increase
May: Aetna
Dec: Humana
(exclusive)
Apr: Expanded to Trauma - TORQ
Jul: SALLY Clinical Trial (2-yrdata)
2021
Jun: Centene
Jul: Anthem (exclusive)
Oct: UHC (exclusive)
Near Universal coverage in the US for MIS SIJF, including >35 payors with >160M exclusively covered lives for iFuse (1)
1. As of October 1, 2021
4
Major Joints Market
LAST
JOINT
S I J O I NT
LARGEST
JOINT
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
SI-BONE Inc. published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 12:07:05 UTC.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE, INC. 
